REGN
Regeneron Pharmaceuticals, Inc.
Stock
$735.20+0.39 (+0.05%)Close Oct 2, 2026
- Operating income, 2025
- $3.6B
- YoY, 2025
- −10.3%
- 5-year CAGR
- 0.0%
- 10-year CAGR
- +11.1%
Operating income
Operating income by fiscal year
| Period | Operating income | YoY |
|---|---|---|
| 2025 | $3.6B | −10.3% |
| 2024 | $4.0B | −1.4% |
| 2023 | $4.0B | −14.6% |
| 2022 | $4.7B | −47.0% |
| 2021 | $8.9B | +150.1% |
| 2020 | $3.6B | +61.9% |
| 2019 | $2.2B | −12.8% |
| 2018 | $2.5B | +21.9% |
| 2017 | $2.1B | +56.3% |
| 2016 | $1.3B | +6.3% |
| 2015 | $1.3B | +51.9% |
| 2014 | $824M | +10.9% |
| 2013 | $743M | +62.3% |
| 2012 | $458M | — |
| 2011 | −$205M | — |
| 2010 | −$97M | — |
| 2009 | −$74M | — |
| 2008 | −$86M | — |